Drug Research
Drug Discovery & Development

monARC starts integration with Roivant's drug development platform

Published 04 May 2018

monARC Bionetworks has started an integration with the drug development platform of Roivant Sciences, a biopharmaceutical company focused on reducing the time and cost of the drug development process.

monARC's multi-disciplinary team of drug developers and technology experts have built disease-specific patient network applications and online tools that prequalify and engage patients during protocol development prior to study initiation.

They have also developed a suite of digital apps, back-end architecture, and telemedicine capabilities to reduce site visits and enable completely virtual clinical trials.

This integrated platform has been crafted to accelerate patient enrollment, improve site selection, reduce protocol amendments, decrease patient dropout rates, permit rapid experimentation with novel apps and devices, and ensure that individuals in remote and underserved communities can participate in clinical trials.

monARC's current customers include academic researchers, biopharmaceutical companies, and medical device manufacturers.

In a pilot program, monARC's platforms yielded clinical trial enrollment 20 times faster than industry benchmarks in idiopathic pulmonary fibrosis and ensured 90% adherence from elderly patients using digital data collection tools like Bluetooth-connected spirometers, weight scales, and activity watches.

monARC founder and CEO Komathi Stem said: "Our core strategy of putting patients first has reduced clinical research timelines.

"Roivant shares our passion for improving the process of developing new medicines for patients, and we are delighted to partner with Roivant as we expand the scope of our work."

Roivant chief information officer Dan Rothman said: "At Roivant, we are constantly iterating and improving how we run clinical trials across our family of companies to enhance the patient experience, minimize time and risk, and generate higher quality data.”

With Roivant's strategic investment, monARC can expand its patient research networks into additional diseases including atopic dermatitis, obesity, and diabetes to help meet growing customer and patient demand.

Mr. Rothman and Wasim Malik, PhD, Chief Digital Strategist at Roivant, will be joining monARC's board of directors and Roivant will collaborate with monARC on five disease areas where companies in the Roivant family are currently conducting clinical research.

Source: Company Press Release